20240208171546.png&width=400&height=400)
A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3/UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors.
Today, Memorial Sloan Kettering Cancer Center (MSK), in collaboration with Miami-based creative agency Alma, launched a bilingual public service campaign to promote the importance of routine cancer screenings.
Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation.
Memorial Sloan Kettering Cancer Center (MSK) and NMDP/Be The Match® today announced the launch of the “American Symphony: Become a Lifesaver” campaign to increase registration of blood stem cell and marrow donors to the national registry and improve access to blood stem cell transplants.
The biennial prize recognizes a new generation of leaders in cancer research
Craig D. Blinderman, MD, has been appointed Chief of the Supportive Care Service at Memorial Sloan Kettering Cancer Center (MSK).
Memorial Sloan Kettering Cancer Center (MSK) today announced a transformative gift from the Commonwealth Foundation for Cancer Research to benefit the Center for Experimental Therapeutics, a multidisciplinary research and drug development group at MSK.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.
Damon Reed, MD, has joined Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Head of the Division of Pediatric Solid Tumors and as Chief of the Pediatric Sarcoma Service.
Memorial Sloan Kettering Cancer Center has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.
Memorial Sloan Kettering Cancer Center (MSK) today announced the creation of The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), a hub for immunotherapy research that will elevate, centralize, and prioritize the full spectrum of immuno-oncology research across the institution. The CCI, made possible by a generous $40 million gift from Henry R. Kravis to honor the visionary leadership of his wife, Marie-Josée Kravis, Vice Chair of the MSK Board of Trustees and a renowned champion of science, will establish a strategic research infrastructure that will seamlessly unite MSK scientists and physicians to further accelerate immunotherapy treatments for people with cancer.
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that eight distinguished MSK nurses and one nursing team were honored with the 2023 Robbins Family Award for Nursing Excellence.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Anaeze Offodile II, MD, MPH, will join the institution as Chief Strategy Officer (CSO) on May 1. Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.
Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS, President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD, Associate Member of the Immunology Program at the Sloan Kettering Institute, will be honored at the 2023 American Association for Cancer Research (AACR) Annual Meeting for their significant contributions to cancer research and care
In this special episode, MSK's Dr. Diane Reidy-Lagunes sits down with renowned journalist and cancer screening advocate Katie Couric at The Paley Center for Media in New York City. After losing her first husband to colon cancer in 1997, Katie made history when she received her first colonoscopy on-air as host of the Today show, inspiring millions of Americans to do the same in a phenomenon known as the Couric Effect. Her role as the “screen queen” has continued ever since, taking on new meaning last year when she revealed her own breast cancer diagnosis.
Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce three faculty are among the 23 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2023.
Memorial Sloan Kettering Cancer Center (MSK) today announced that LaKisha Mack, MSHA, will join the institution as the inaugural Chief Administrative Officer (CAO). In her role at MSK, Mack will direct the evolution and improvement of all business processes.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents.
Memorial Sloan Kettering Cancer Center Names Lawrence Schwartz, MD, New Chair of the Department of Radiology
Stigma can have profound and lasting effects, and studies have shown that people living with lung cancer may encounter challenges in receiving the support they need from their social network and healthcare providers. Memorial Sloan Kettering Cancer Center (MSK) is committed to helping eliminate the stigmas associated with a lung cancer diagnosis and is working to raise awareness in collaboration with other national organizations.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.
Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has been selected to serve as its next President and Chief Executive Officer.
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that 13 distinguished MSK nurses and one nursing team were recognized with the 2022 Robbins Family Award for Nursing Excellence. During National Nurses Week (May 6 – 12), MSK recognizes outstanding nurses for exemplary service.
Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Fumiko Chino, MD; Craig B. Thompson, MD; and Jedd D. Wolchok, MD, PhD, FASCO, have been honored by the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation, with three prestigious awards. These special awards, including the inaugural Excellence in Equity Award, the Science of Oncology Award, and the David Karnofsky Award, are awarded to researchers and global oncology leaders who have reshaped cancer care around the world and are among the highest honors bestowed by ASCO. Dr. Chino, Dr. Thompson, and Dr. Wolchok will be presented with the awards at the 2022 ASCO Annual Meeting in Chicago on June 3–7, 2022.
Five Memorial Sloan Kettering (MSK) faculty are among the 33 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2022.
Today, Craig B. Thompson announced his intention to step down as President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK) and has asked the Boards of Trustees and Governing Trustees to begin a search for his successor. Thompson will continue in his role until the Board identifies his successor.
A new study from Memorial Sloan Kettering Cancer Center (MSK) provides important insights into cancer metastasis.
Memorial Sloan Kettering Cancer Center (MSK) today announced the creation of The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project to spur the next revolution of preclinical research, discovery, and treatment. The new initiative, made possible by a generous $100 million gift from The Marie-Josée and Henry R. Kravis Foundation, will bring together teams of researchers from across the institution to explore the many interconnected elements that contribute to the relapse of cancer — the key driver of cancer deaths — guided by a holistic, strategic vision.
.jpg&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology. In this role, Evard will be responsible for the overall design and execution of the organization’s digital strategy.
Launched with a $100 million commitment, the initiative will focus on the most impactful early-stage, translational cancer research.
Saad Usmani, MD, has been named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from the Levine Cancer Center in North Carolina and succeeds C. Ola Landgren, MD, PhD, who previously served in this role for six years.
Memorial Sloan Kettering Cancer Center (MSK) today announced a generous $50 million gift from Mike and Maria Repole and the Nonna’s Garden Foundation to establish The Nonna’s Garden Foundation Initiative for Cancer Care and Research at MSK.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical trial ever to study the use of stereotactic body radiation therapy (SBRT) in treating oligoprogressive metastatic lung and breast cancers. These findings will be presented during this year’s American Society for Radiation Oncology (ASTRO) meeting in Chicago.
Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 64 recipients of the prestigious 2021 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Perry will receive $1.5 million in direct costs split into two multi-year segments.
Deb Schrag, MD, MPH, has been named the new Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
Memorial Sloan Kettering Cancer Center (MSK) today announced a $25 million gift from Louis V. Gerstner, Jr. to create the Louis V. Gerstner, Jr. Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the Gerstner Physician Scholars Program will advance promising scientific research and further the careers of outstanding junior faculty.
Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.
While overall cancer cases are declining, they are on the rise in older adolescents and young adults. Today, Memorial Sloan Kettering Cancer Center (MSK) announces the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers (the Stuart Center), dramatically expanding MSK’s already robust efforts to address the very specific, and often unmet, needs of this patient population.
New data published in the New England Journal of Medicine (NEJM) and featured at the European Society for Medical Oncology (ESMO) Congress 2021 highlights a promising new treatment for individuals with HER2-mutant non-small cell lung cancer (NSCLC).
Memorial Sloan Kettering Cancer Center (MSK) has appointed Tracy Gosselin, PhD, RN, AOCN, NEA-BC, FAAN, as Senior Vice President, Chief Nurse Executive, and Chair of Nursing effective November 2021. Dr. Gosselin currently serves as Chief Nursing & Patient Care Services Officer, Duke University Hospital.
The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number one center for ear, nose, and throat care by U.S. News & World Report in its annual Best Hospitals listing. MSK has been consistently ranked among the top two cancer centers in the country for over 30 years.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.
During a virtual commencement ceremony on Wednesday, May 19, 2021, at 3:00 PM ET, Memorial Sloan Kettering Cancer Center (MSK) will recognize seven Gerstner Sloan Kettering (GSK) 2021 graduates and honor Joan Argetsinger Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine and a Howard Hughes Medical Institute Investigator, with the 2021 Honorary Degree and the Memorial Sloan Kettering Medal for Outstanding Contributions to Biomedical Research.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
